Celldex Therapeutics, Inc. Message Board
-
I thought the recent deluge of financial press coverage would have filled the gap nicely between real news releases. This is the weakness also that Cramer told his minions to buy into. Plus industy dealmaking is on the upswing and the overall market is up to boot. I'd have expected more buying and less selling (rather than the other way around) all things considered. "breathrough status, partnership, and approval (to which I might add starting the accelerated phase III study for CDX-011) you're correct about are hanging in the balance, but it is precisely those things and this situation that makes Celldex a compelling buy here and now. Plus, I just prefer days when then stock goes up versus days when it goes down because it makes me feel warm and fuzzy all over. :)
Sentiment: Strong Buy
-
could shed some light on the erratic trading of shares of Celldex the last couple days, but I suspect the real reason for the selloff is quite simply a collusion among the big players trading in Celldex to take your shares. The thirst for shares has become insatiable in the past two weeks. This is evidenced by the average volume that if you had told ANY of us last year would be the daily volume today, then it would have resulted in you being hung out to dry). This demand increase with such a small float is the reason players are collaborating in creating low volume share price declines and taking out stops of unsuspecting retail investors. This pattern of manipulation has happened over and over again with this stock. The only way to avoid this is to remove the stops from your Celldex shares.
Sentiment: Strong Buy
-
J&J was up on the news of Aragon BO yesterday. Deals for cancer drugs are hot commodities for Big Pharma right here and now. Nobody knows if or when Celldex will make a deal for any of the drugs in their pipeline, but if they do (and it could happen at any time) it will be a huge catalyst for Celldex share price. The Aragon deal with J&J illustrates that these biotech developed drugs are in demand, can and will be taken by Big Pharma if the opportunity presents itself.
Sentiment: Strong Buy
-
If only one Aragon cancer drug prospect is worth $1BB, then what is Celldex with 2 late-stage cancer drugs and a pipeline of early -stage work that easily idoubles th evalue worth to Big Pharma? This deal was for ARA-509 only and Aragon gets to spin out the rest of their development pipeline in a new biotech venture (ala Medarex deal)
Sentiment: Strong Buy
-
In a billion-dollar cancer drug buyout, agreeing to buy Aragon Pharmaceuticals and its promising next-gen prostate cancer drug for $650 million in cash and up to $350 million in milestones. The deal gives J&J ($JNJ) complete control over a combo approach with blockbuster potential that could help further improve the rapidly changing standard of care in prostate cancer. Cancer drug--ARN-509--was built around the idea that if you can build a better anti-androgen drug, you can offer new hope to castration-resistant prostate cancer patients. The biotech saw its therapy as a logical second-generation approach to Medivation's Xtandi, offering some big potential as a future combo package with J&J's Zytiga--another cancer drug that J&J picked up in a billion dollar deal to buy Cougar Biotechnology.
Sentiment: Strong Buy
-
Only 160,000 shares traded in first hour
Sentiment: Strong Buy
-
overal market is doing well today. If volume picks up this afternoon we may close up. Press has been very favorable and prolific, so I'm a little surprised share price is on low end of recent gains. Any positive news from Celldex directly should send share soaring.
Sentiment: Strong Buy
-
1/2 the volume today was over $16/share all in the morning. Then they took it down on low volume (1/6 total) midday between $16-$15.50 and bought up 1/3 the volume of shares at the end of the day at at 20% discount to the morning pricing. This is programmed manipulation by collusion among traders to take your shares gentleman!
Sentiment: Strong Buy
-
What does w/w increase of 16% translate into for M/M for June? (i.e. if this great w/w trend continues for the entire month, then what will M/M fof full months May to June be?)
Sentiment: Strong Buy
- Reply to
For those who doubt CLDX can continue a strong uptrend.....
by like2invest1958 •Jun 17, 2013 7:29 AMyes, Celldex could easily be the next Pharmacyclics. I'm surprised it has taken this long for the word to get out about that. Truth be told we are still significantly undervalued.
Sentiment: Strong Buy
-
I don't think we know exactly what the deal is for the SGEN linker technology, but CEO has stated that "it was an early deal" meaning it was not as expensive as more reent deals that SGEN is making for same technology. They can't make competing CDX-011- that's for sure.
Sentiment: Strong Buy
-
I think it's possible. Merck is a sleeping giant, so anything is possible. Has anyone done an analysis of any portential for synergistic effect of Celldex's pipeline compounds with merk's the PD-1 drug? Not that this would be the only reason for a collaboration (Celldex's drugs stand on their own merits) but if a twist was in there for co-administration there coudl be nice premium on any deal with Merck.
Sentiment: Strong Buy
- Reply to
Celldex: A Bolt-on Turn-Key Immunotherapy Division for Big Pharma?
by mymandon •Jun 16, 2013 10:34 PMThe only thing I see between here and there is the savvy suitor materializing willing to pay for the work that has been done to create the potential that Celldex management and scientists have created. The cost to buy Celldex coutright may be out of the comfort zone of most large pharma and large biotech CEOs, but I suggest here that the value would return many fold over for just such an venture in a relatively short period of time in drug develpoment terms. We'll see where the trade winds take Celldex in the future, but without a doubt in my mind it will be on an even keel toward bright and enduring success.
Sentiment: Strong Buy
-
Most discussions of potential Celldex dealmaking has been around either global (ex-US) marketing or line extention development of Rindo or CDX-011 with other possibilities of full rights potential of the deeper pipeline (phase II and earlier compounds). What has largely been dismissed is any possibilty of Celldex being taken into a larger entity that lacks large molecule expertise and/or late-stage products in a single transaction. The general thinking is that Celldex has "too much" potential in the deep pipeline and any takeover would discount these products (several of which could easily eclipse Rindo and CDX-011 together in peak sales) when they come to market more than a couple years from now. I actually think there are now only three possibilities. One is to go it alone with Rindo and CDX-011 leading the way and funding the deep pipeline into fruition. This is very doable because Celldex has it's own manufacturing facility and marketing of cancer these cancer treatments is to a limited number of specialists not requiring a huge salesforce. This approach seems like the highest probabilty. The second approach would be a series of partnerships for the various compounds in development with one or more collaborating companies. This could include large upfront and milestone payments that coudl fund the deep pipeline development for more than a few years into the future. However, I personnally think this coudl get messy and once initial deals are in place woudl make future deals (full buyout by a different company than the one with key partnerships) unlikely and take away the one ace in the hole Celldex is now holding- that is, the 100% ownership of it's intellectual property. This leaves the full immersion into larger entity as perhaps the best way forward allowing the value created in Rindo and CDX- 011 to be realized by stakeholders and the value of the line extention potential of these and the deep pipeline to be developed by a savvy suitor.
Sentiment: Strong Buy
-
Good point. People forget that the targeted therapeutic approach comes with companion diagnostics and has very high probability of success. That excellent probability figure is lost on most analyses and needs to be factored into any risk assessment to get it correct. Bottom line here is that Celldex is going to be commercially successful with both Rindo and CDX-011 and the only thing between here and there is time. The probabilty of success is very, very high here and moreso than most spec biotech investments out there. Agree there is huge upside still to go and biggest risk will be getting out on a double and then watching it quadruple or more in next year or two.
Sentiment: Strong Buy
-
The modus operandi of CEO (Anthony Marucci) and Celldex is to maintain independence until another firm (a big pharma or big biotech) provides compelling reason to do otherwise. With cash in the bank and not one but two effective late-stage drugs in development (not to mention deep pipeline of innovative early development programs) Celldex can use their unique intellectual property position (100% ownership of every product in the pipeline) as an ace in the hole for any negotiations regarding collaborative partnership (and/or buyout). The aformentioned is highly significant and can not be discounted in any evaluation of the enterprise value of Celldex Therapeutics. Celldex has the goods to go it alone in the cancer therapy market place with both CDX-011 and Rindo and any business deals and/or interactions with other firms will be on Celldex's terms and will benefit stakeholders of Celldex becasue of the uniquely advantageous position they are in with regard to intellectual property, financial fundamentals and the targeted cancer drugs in development that have proven effective in the treament of difficult to treat and life-threatening diseases where no other viable options are available.
Sentiment: Strong Buy
-
What does w/w increase of 16% translate into for M/M for June? (i.e. if this great w/w trend continues for the entire month, then what will M/M fof full months May to June be?)
Sentiment: Strong Buy
-
Is he sticking it to them ?
Sentiment: Strong Buy
-
Agree losses are piling up for anyone with short interest in Celldex. They were blind-sided by the one two punch of 1) non-dilutive financing earlier in the year and 2) Cramer and subsequent market news coverage that exposed the hidden value here to teh broader market. They were sure the financing would drop the stock back to $5 back in February, then thought for certain the fact that Celldex was not presenting data at ASCO meant that ASCO was going to be a bust, too. Add to that Celldex has not been a good stock to short on the science and portfolio (since December CDX-011 data) and any short interest is now betting against what I think are huge and ever dwindling odds. The macro environment of the market is also improving after mre than a week of consolidation after reaching all time highs. Big trouble ahead for shorts, but good news is we are in long positions and swimming downstream with momentum, science and fundamentals in our favor. New higher share price range is coming gentlemen.
Sentiment: Strong Buy
- Reply to
Back to back media attention, among the three running strong contenders, with only Celldex addressing
by neshua10 •Jun 15, 2013 10:50 PMThis piece is referring to Celldex's off-the shelf dendritic cell vaccine platform (which means no need for allographic transplatation of patients own cells that is expensive and laborious approach) based on Ralph Steinman's Nobel Prize winning research on using dendritic cells to boost immunity. CDX-1401 is the first of these and is (from Celldex's website) "a fusion protein consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor DEC-205 linked to the NY-ESO-1 tumor antigen. The NY-ESO-1 antigen is expressed in a variety of cancer cells. Targeting protein antigens to the DEC-205 receptor on dendritic cells was pioneered by the late Ralph Steinman, MD, a member of Celldex's Scientific Advisory Board. Dr. Steinman received the 2011 Nobel Prize in Physiology or Medicine for his discovery of the dendritic cell and its role in adaptive immunity. In preclinical studies, CDX-1401 has been shown to induce potent and broad immunity. The Phase 1 study of CDX-1401 is the first clinical study to demonstrate that an off-the-shelf vaccine that targets dendritic cells in vivo through DEC-205 can safely lead to robust humoral and cellular immunity when combined with TLR agonists in cancer patients - overcoming a significant challenge in the development of protein based vaccines." This has broad and far reaching application for cancer and other difficult to treat disease.
Sentiment: Strong Buy